跳至主要内容
临床试验/NCT01860781
NCT01860781已完成4 期

The Effect of Paliperidone Palmitate in Schizophrenia: A Prospective Naturalistic Case Series Study

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2011年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
30
试验地点
1
主要终点
CGI-S,I: Clinical Global Impression-Severity, Improvement

研究概览

简要总结

The purpose of this study is the evaluation of effectiveness of paliperidone palmitate within three different group of schizophrenia patients.

详细描述

In this study, the investigators are going to examine the effectiveness of paliperidone palmitate after changing from other antipsychotics. This study design is a Prospective Naturalistic Case Series Study. The effectiveness of paliperidone would be compared within three different groups of schizophrenia. Investigators would also assess the safety during 24 weeks follow up period.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18 ~ 65
  • Patient with schizophrenia according to DSM-IV criteria
  • Patient have signed on the informed consent, and well understood the objective and procedure of this study.
  • PANSSS total score <120
  • each Score of disorganized thought, paranoia hallucinatory behavior, abnormal tbought contests < 16
  • three different groups ( other antipsychotics refractory schizophrenia patitents : CGI> 4 chronic akathisia : DIEPSS overall severity >1, at least 1 month lasting symptoms poor compliance schizophrenia : CRS <3)
  • Competent patient who is manage to answer the questionnaires.
  • In case of female at child-bearing age, consent to use appropriate contraceptive methods(oral pill, contraceptive injection, intrauterine device, double barrier method and contraceptive patch) during entire duration of this study.

排除标准

  • No history of antipsychotics prescription
  • History of NMS(Neuroleptic malignant syndrome)
  • Allergic reaction or hypersensitive reaction of risperidone or paliperidone ER
  • clozapine medication within 1 month before screening
  • SSRI, MAOI, TCA medication within 2 months
  • Lithium, valproic acid, carbamazepine, topiramate, lamotrigine medication starting within 2 months
  • patient who is supposed to be impossible to participate to this study due to clinical risk of suicide or aggressive behavior based on clinician's opinion
  • current or previous history of drug depedence according to DSM-IV
  • Pregnant or breast-feeding female patient
  • Significant biochemical or hematological abnormality or abnormal finding of urinalysis, based on clinician's opinion
  • history of cardiac disease, which is related to QT prolongation(sick sinus, complete AV block, CHF, ventricular tachycardia, hypokalemia or hypocalcemia)
  • History of participating to other investigational drug trial within 1month prior to screening
  • Investigator or employee at clinical trial center, personnel related to investigator or trial center on this or other study, or family of employee or investigator

研究组 & 干预措施

paliperidone palmitate

Experimental

paliperidone palmitate

干预措施: paliperidone palmitate (Drug)

结局指标

主要结局

CGI-S,I: Clinical Global Impression-Severity, Improvement

时间窗: 24 weeks

次要结局

  • PANSS: Positive and Negative Syndrome Scale(24 weeks)
  • CRS: Clinician Rating Scale(24 weeks)
  • KDAI-10: Korean Drug Attitude Inventory-10(24 weeks)
  • injection site pain -VAS: Visual Analog Scale(24 weeks)
  • LUNSERS: Liverpool University Neuroleptic Side Effect Rating Scale(24 weeks)
  • SWN: Subjective Well-being Under Neuroleptic Treatment(24 weeks)
  • DIEPSS: Drug-Induced ExtraPyramidal Symptoms Sclae(24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yong Min Ahn

professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验